Magacho Leopoldo, Reis Ricardo, Shetty Rajesh K, Santos Lúcia C, Avila Marcos P
Ophthalmology Department, Federal University of Goiás, Goiânia, Brazil.
Ophthalmology. 2006 Mar;113(3):442-5. doi: 10.1016/j.ophtha.2005.11.011. Epub 2006 Feb 3.
To compare latanoprost with the fixed-combination latanoprost-timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication.
Prospective randomized clinical trial.
Glaucoma or ocular hypertension patients receiving a combined treatment of timolol 0.5% and another nonprostaglandin medication (pilocarpine 4%, alpha-agonist, or a topical carbonic anhydrase inhibitor) underwent a 30-day washout of their medications. A masked observer then measured their intraocular pressure (IOP). The subjects were randomized to either latanoprost or fixed-combination latanoprost-timolol eyedrops to use once daily at 7 am. The IOP was measured again 30 days after the patients started using one of the study drugs by the same examiner at the same time.
Comparison of the study medications' hypotensive effect.
Fifty-three eyes (28 in the latanoprost group and 25 in the latanoprost-timolol group) from 28 patients were included in the study. The IOP reduction was greater in both study groups compared with the previous combination therapy with timolol and another nonprostaglandin medication in millimeters of mercury (7.7+/-2.3 vs. 5.5+/-2.3, P<0.001, for the latanoprost group; 8.5+/-3.5 vs. 6.3+/-2.7, P<0.001, for the latanoprost-timolol group) and percentage (35.8+/-8.2% vs. 25.6+/-8.9%, P<0.001, for the latanoprost group; 38.6+/-8.7% vs. 28.6+/-9.0%, P<0.001, for the latanoprost-timolol group). There was no statistical difference between latanoprost and fixed-combination latanoprost-timolol in reducing IOP, in either millimeters of mercury (P = 0.3) or percentage (P = 0.2).
Both latanoprost and fixed-combination latanoprost-timolol may be viable substitutes for timolol and another nonprostaglandin medication in glaucoma or ocular hypertension patients.
比较拉坦前列素与拉坦前列素 - 噻吗洛尔固定复方制剂，用于从噻吗洛尔与另一种非前列腺素类药物联合治疗转换过来的青光眼或高眼压症患者。
前瞻性随机临床试验。
接受0.5%噻吗洛尔与另一种非前列腺素类药物（4%毛果芸香碱、α受体激动剂或局部碳酸酐酶抑制剂）联合治疗的青光眼或高眼压症患者，停用其药物30天进行洗脱期。然后由一名盲法观察者测量其眼压（IOP）。受试者被随机分为使用拉坦前列素或拉坦前列素 - 噻吗洛尔固定复方滴眼液，每天上午7点使用一次。患者开始使用其中一种研究药物30天后，由同一名检查者在同一时间再次测量眼压。
比较研究药物的降压效果。
28例患者的53只眼（拉坦前列素组28只眼，拉坦前列素 - 噻吗洛尔组25只眼）纳入研究。与之前噻吗洛尔与另一种非前列腺素类药物联合治疗相比，两个研究组的眼压降低幅度在毫米汞柱方面更大（拉坦前列素组为7.7±2.3 vs. 5.5±2.3，P<0.001；拉坦前列素 - 噻吗洛尔组为8.5±3.5 vs. 6.3±2.7，P<0.001），在百分比方面也更大（拉坦前列素组为35.8±8.2% vs. 25.6±8.9%，P<0.001；拉坦前列素 - 噻吗洛尔组为38.6±8.7% vs. 28.6±9.0%，P<0.001）。拉坦前列素与拉坦前列素 - 噻吗洛尔固定复方制剂在降低眼压方面，无论是在毫米汞柱（P = 0.3）还是百分比（P = 0.2）方面均无统计学差异。
对于青光眼或高眼压症患者，拉坦前列素和拉坦前列素 - 噻吗洛尔固定复方制剂都可能是噻吗洛尔与另一种非前列腺素类药物的可行替代药物。
